Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Jerini has submitted its new drug application for icatibant in the treatment of genetic disorder hereditary angioedema.
Subscribe to our email newsletter
After receiving technical clearance of the electronic common technical document from the FDA, the regulatory review period will begin, the German drug discovery company said.
Jens Schneider-Mergener, CEO of Jerini, said: “We are extremely pleased to have initiated the submission process for icatibant. This underlines our strategy of bringing icatibant to HAE patients in the US as well as in Europe.”